Recovery from remifentanil after plasmapheresis in a paediatric patient with myasthenia gravis [2]

Paediatric Anaesthesia

Volumn 13, Issue 9, 2003, Pages 842-844

  Hepaǧuslar, Hasan ^a   Öztekn, Sermin ^a   Çapar, Emine ^a   Elar, Zahide ^a  

^a DOKUZ EYLUL UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; BUPIVACAINE; CHOLINESTERASE INHIBITOR; FENTANYL; FLUOXETINE; HUMAN ALBUMIN; IMMUNOGLOBULIN; LOCAL ANESTHETIC AGENT; NITROUS OXIDE; OXYGEN; PARACETAMOL; PREDNISOLONE; PROPOFOL; PYRIDOSTIGMINE; REMIFENTANIL; TENOXICAM;

ADOLESCENT; ANESTHESIA INDUCTION; ARTIFICIAL VENTILATION; CAPNOGRAPHY; CASE REPORT; CONVALESCENCE; DISEASE SEVERITY; ENDOTRACHEAL INTUBATION; FEMALE; HUMAN; INTENSIVE CARE UNIT; INTRAVENOUS ANESTHESIA; LETTER; MYASTHENIA GRAVIS; OXYGEN THERAPY; PLASMAPHERESIS; PRIORITY JOURNAL; THYMECTOMY; TONSILLECTOMY;

ADOLESCENT; ANALGESICS, OPIOID; ANESTHESIA RECOVERY PERIOD; ANESTHETICS, INTRAVENOUS; FEMALE; FENTANYL; HUMANS; INTUBATION, INTRATRACHEAL; MONITORING, INTRAOPERATIVE; MYASTHENIA GRAVIS; PIPERIDINES; PLASMAPHERESIS; PROPOFOL; THYMECTOMY;

EID: 0345689400     PISSN: 11555645     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1460-9592.2003.01157.x     Document Type: Letter

References (15)

1. Davis L, Britten JJ, Morgan A. Cholinesterase. Its significance in anaesthetic practice. Anaesthesia 1997; 52: 244-260.
2. Egan TD, Lemmens HJ, Fiset P et al. The pharmacokinetics of the new short-acting opioid remifentanil (G187084B) in healthy adult male volunteers. Anesthesiology 1993; 79: 881-892.
3. Clark WF, Rock GA, Buskard N et al. Therapeutic plasma exchange: an update from the Canadian Apheresis Group. Ann Intern Med 1999; 131: 453-462.
4. Kuks JBM, Skallebaek D. Plasmapheresis in myasthenia gravis. A survey. Transfus Sci 1998; 19: 129-136.
5. Evans RT, MacDonald R, Robinson A. Suxamethonium apnoea associated with plasmapheresis. Anaesthesia 1980; 35: 198-201.
6. Naik B, Hirshhorn S, Dharnidharka VR. Prolonged neuromuscular block due to cholinesterase depletion by plasmapheresis. J Clin Anesth 2002; 14: 381-384.
7. Rosow CE. An overview of remifentanil. Anesth Analg 1999; 89: S1-S3.
8. Manullang J, Egan TD. Remifentanil's effect is not prolonged in a patient with pseudocholinesterase deficiency. Anesth Analg 1999; 89: 529-530.
9. Davis PJ, Stiller RL, Wilson AS et al. In vitro remifentanil metabolism: the effects of whole blood constituents and plasma butyrylcholinesterase. Anesth Analg 2002; 95: 1305-1307.
10. Culley DJ, Crosby G. Neurologic disease. In: Sweitzer B, ed. Handbook of Preoperative Assessment and Management. Philadelphia: Lippincott Williams & Wilkins, 2000: 255-284.
11. Lorimer M, Hall R. Remifentanil and propofol total intravenous anaesthesia for thymectomy in myasthenia gravis. Anaesth Intens Care 1998; 26: 210-212.
12. Granell Gil M, Garcia Aguado R, Ferrandiz Roca L et al. The Fastrach laryngeal mask, sevoflurane and remifentanil: an anesthetic alternative for the myasthenic patient. Rev Esp Anestesiol Reanim 2001; 48: 85-88.
13. Vincent A, Palace J, Hilton-Jones D. Myasthenia gravis. Lancet 2001; 357: 2122-2128.
14. Wood GJ, Hall GM. Plasmapheresis and plasma cholinesterase. Br J Anaesth 1978; 50: 945-949.
15. Jackson SH, Bailey GWH, Stevens G. Reduced plasma cholinesterase following haemodilutional cardiopulmonary bypass. Anaesthesia 1982; 37: 319-320.